Today: 13 June 2026
Bank of America stock slips as Trump credit-card cap clouds BAC earnings
13 January 2026
2 mins read

Bank of America stock slips as Trump credit-card cap clouds BAC earnings

New York, Jan 13, 2026, 11:55 AM EST — Regular session

  • Shares of Bank of America slipped as traders grappled with new policy risks tied to credit-card pricing
  • A steady U.S. inflation report left the interest-rate outlook uncertain for banks
  • Investors are gearing up ahead of Bank of America’s upcoming quarterly results and guidance

Shares of Bank of America Corp (BAC) dropped 0.9% to $54.72 in late-morning trading Tuesday in New York, as investors weighed a proposed cap on credit-card interest rates.

The stock reacted after U.S. consumer prices rose 0.3% in December, matching expectations, with a 2.7% increase year-on-year. Core CPI, excluding food and energy, climbed 0.2% monthly and 2.6% annually. The Fed is widely expected to hold its policy rate steady at the Jan. 27-28 meeting, the report said. “The recent run of figures suggests inflation has peaked,” said Michael Pearce, chief U.S. economist at Oxford Economics. Reuters

For banks, rates directly affect net interest income — the gap between earnings on loans and securities and costs on deposits. The key issue now: will the current rate environment remain favorable enough to sustain margins as credit quality remains stable?

The bigger headline risk is political. On Monday, Bank of America dropped 1.6% in early trading after President Donald Trump proposed a one-year cap on credit-card interest rates at 10% starting Jan. 20; JPMorgan slid 2.5%, Citigroup tumbled 3.7%, and Wells Fargo declined 1.5%. “It would take an Act of Congress for such rate caps to be in place,” UBS Global analysts noted. Reuters

Bank trade groups are pushing back hard. The Electronic Payments Coalition warned that 82% to 88% of open credit-card accounts—those linked to credit scores under 740—would face closure or severe restrictions if a 10% interest rate cap is imposed. “A one-size-fits-all government price cap may sound appealing, but it wouldn’t help Americans,” said EPC executive chairman Richard Hunt. Reuters

Analysts warn the rate cap clashes with the fundamental economics of unsecured lending, especially hitting subprime borrowers with shaky credit. Truist Securities said, “We estimate it would swing the business to unprofitable if enacted, with subprime credit cards hardest hit.” Reuters

JPMorgan’s shares dropped roughly 2.8% on Tuesday despite beating quarterly profit forecasts. CFO Jeremy Barnum warned during the earnings call that a cap “would be very bad for consumers, very bad for the economy.” Reuters

Investors eye Bank of America’s net interest income trends, credit-card delinquencies, charge-offs, and any reserve changes for future loan losses. Expenses remain crucial, as does the outlook on deal fees and trading following a turbulent quarter for markets.

The policy overhang works both ways. Should Congress begin shifting the cap, issuers might respond by tightening credit limits, hiking annual fees, or scaling back rewards. These moves could dampen card growth and weigh on consumer spending. Worse delinquency trends would only pile on more pressure.

Bank of America is set to release its fourth-quarter 2025 earnings before the market opens Wednesday, with the report due around 6:45 a.m. ET. The company’s conference call will follow at 8:30 a.m. ET. Investors will be tuned in for any commentary on the credit-card cap and potential ripple effects ahead of Jan. 20.

Stock Market Today

  • Telix Pharmaceuticals Phase 3 ProstACT Safety Data Boosts Investment Outlook
    June 12, 2026, 8:05 PM EDT. Telix Pharmaceuticals (ASX:TLX) announced early Phase 3 ProstACT trial data for TLX591-Tx in metastatic castration-resistant prostate cancer, demonstrating an acceptable safety and tolerability profile with no new safety concerns. The lower kidney and salivary gland exposure compared to existing therapies could signal a differentiated advantage. This supports Telix's shift from diagnostics to higher-value therapeutics but hinges on upcoming pivotal trial results. A new U.S. collaboration with United Imaging aims to enhance theranostics workflow and commercial scale. Despite promising clinical progress, risks include regulatory scrutiny following an SEC subpoena over prostate cancer disclosures. Analysts forecast 22.7% annual revenue growth to A$1.2 billion by 2029, with an 85% upside to Telix's current price. Market watchers weigh potential regulatory and execution challenges against long-term growth prospects in theranostics.

Latest articles

SGH Limited Holds Back as ASX 200 Pushes Higher Before FY26 Results

SGH Limited Holds Back as ASX 200 Pushes Higher Before FY26 Results

13 June 2026
SGH closed at A$41.51, up 0.70% but underperformed the S&P/ASX 200’s 1.98% surge, as investors weighed solid cash flow and Boral margin gains against a high 36.03 P/E, mixed demand, and M&A risk; the next key catalyst is FY26 results on August 11, with analysts’ average target at A$47.64, 14.76% above Friday’s close.
NCR Voyix Rallies 10% After Investors Shift on Turnaround Bets

NCR Voyix Rallies 10% After Investors Shift on Turnaround Bets

13 June 2026
NCR Voyix soared 10.25% to $7.85, far outpacing the market, as investors focus on the company’s 2026 cash-flow and earnings targets; the next key catalyst is the Q2 2026 earnings update, with stock valuation appearing low if management delivers on margin and cash-flow goals, but risks remain with declining reported revenue and high debt.
Dow Jones today: DJIA slips from record as Visa and banks weigh after CPI
Previous Story

Dow Jones today: DJIA slips from record as Visa and banks weigh after CPI

Roblox stock jumps as BMO flags a breakout game and Feb. 5 earnings loom (RBLX)
Next Story

Roblox stock jumps as BMO flags a breakout game and Feb. 5 earnings loom (RBLX)

Go toTop